Table 2.
Baseline characteristics of the patients
| Authors, year | MacDonald et al 201012 | Jones et al 201313 | Hunter et al 201414 | Di Biase et al 201615 | Prabhu et al 201716 | Marrouche et al 201817 |
|---|---|---|---|---|---|---|
| Age Mean ± SD |
63.3 ± 7.5 | 63 ± 9.5 | 57.4 ± 11 | 62 ± 10 | 59 ± 11 | 64 (median) |
| Persistent AF, % | 100 | 100 | 100 | 100 | 100 | 70 |
| BMI | 30 ± 5.6 | 29 ± 4.6 | NA | 30 ± 8 | 30 ± 7.5 | 29.1 |
| Hypertension, % | 61 | 33 | NA | 45 | 39 | 72 |
| Diabetes, % | 26 | 23 | NA | 22 | 12 | 28 |
| Prior TIA/stroke, % | 9.8 | 11.8 | NA | NA | 6.1 | 12 |
| COPD, % | 22.0 | 13.7 | NA | NA | NA | NA |
| OSA, % | NA | NA | NA | 45 | 36 | NA |
| NYHA class, % | ||||||
| NYHA class I | 0 | 0 | 0 | NA | NA | 11 |
| NYHA class II | 10 | 52 | 45 | NA | NA | 59 |
| NYHA class III | 90 | 48 | 55 | NA | NA | 28 |
| NYHA class IV | 0 | 0 | 0 | NA | NA | 2 |
| NICM, % | 51.4 | 67.5 | 74 | 38 | 100 | 60 |
| Amiodarone/antiarrhythmic, % | NA | 34 | 53.8 | 0 | 24 | 28 |
| ACEI/ARB, % | 95 | 98 | NA | 92 | 94 | 94 |
| Beta blocker, % | 88 | 92 | NA | 76 | 97 | 92 |
| Aldosterone antagonist, % | 31.6 | 36.5 | NA | 45 | 33 | NA |
| Digoxin, % | 51.3 | 54 | NA | NA | NA | 20 |
Abbreviations: ACEI/ARB, Angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; NICM, Nonischemic cardiomyopathy; NYHA, New York Heart Association; OSA, Obstructive sleep apnea; TIA, Transient ischemic attack.